Clinical Trial Update: Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis [Phase 3]

View source ↗

Summary

Phase 3 trial investigating interleukin-11 for prevention and treatment of radioactive oral mucositis in nasopharyngeal carcinoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Interleukin-11 (interleukin-11)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: UNKNOWN